Trial Profile
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms COMPLETE- PsA
- Sponsors Abbott Canada; AbbVie
- 15 Jan 2022 Primary endpoint has been met (Change in the Disease Activity Score - 28 (DAS-28) as per Results published in The Journal of Rheumatology
- 15 Jan 2022 Results published in The Journal of Rheumatology
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.